Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms LUCENT 2
- Sponsors Eli Lilly and Company
- 17 Jan 2024 Planned End Date changed from 29 Jun 2025 to 20 Dec 2024.
- 26 Oct 2023 According to an Eli Lilly and Company media release, announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh for the treatment of moderately to severely active ulcerative colitis (UC) in adults based on results from the LUCENT 1 & 2 trials.
- 17 Oct 2023 Results of pooled analysis from LUCENT-1 and LUCENT-2 assessing if the addition of BU improvement to clinical re-sponse or remission was associated with better work productivity presented at the 31st United European Gastroenterology Week